WO2010130832A3 - Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions - Google Patents

Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions Download PDF

Info

Publication number
WO2010130832A3
WO2010130832A3 PCT/EP2010/056659 EP2010056659W WO2010130832A3 WO 2010130832 A3 WO2010130832 A3 WO 2010130832A3 EP 2010056659 W EP2010056659 W EP 2010056659W WO 2010130832 A3 WO2010130832 A3 WO 2010130832A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequences
polypeptides
dickkopf
diseases
Prior art date
Application number
PCT/EP2010/056659
Other languages
French (fr)
Other versions
WO2010130832A2 (en
Inventor
Karen Cromie
Bruno Dombrecht
Peter Verheesen
Georgios Sabatakos
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of WO2010130832A2 publication Critical patent/WO2010130832A2/en
Publication of WO2010130832A3 publication Critical patent/WO2010130832A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Amino acid sequences are provided that are directed against Dickkopf-1 (Dkk-1), as well as compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, compounds, constructs and/or polypeptides, and to uses of such amino acid sequences, compounds, constructs, polypeptides, and/or compositions, for prevention and/or treatment of diseases and disorders associated with bone loss and/or osteolytic lesions.
PCT/EP2010/056659 2009-05-15 2010-05-14 Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions WO2010130832A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17862309P 2009-05-15 2009-05-15
US61/178,623 2009-05-15

Publications (2)

Publication Number Publication Date
WO2010130832A2 WO2010130832A2 (en) 2010-11-18
WO2010130832A3 true WO2010130832A3 (en) 2011-04-21

Family

ID=42727639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/056659 WO2010130832A2 (en) 2009-05-15 2010-05-14 Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions

Country Status (1)

Country Link
WO (1) WO2010130832A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US8846041B2 (en) 2010-03-24 2014-09-30 Genentech, Inc. Anti-LRP6 antibodies
WO2012175741A2 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SI2723769T2 (en) 2011-06-23 2022-09-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP4350345A2 (en) 2011-06-23 2024-04-10 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
JP7325928B2 (en) 2014-05-16 2023-08-15 アブリンクス エン．ヴェー． Improved immunoglobulin variable domains
EP3143403B1 (en) 2014-05-16 2021-10-27 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
RU2609627C2 (en) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
US10328143B2 (en) * 2014-10-24 2019-06-25 Peptidream Inc. Hemagglutinin-binding peptide
NO2768984T3 (en) 2015-11-12 2018-06-09
PL3374392T3 (en) 2015-11-13 2022-03-28 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
CA3005488A1 (en) 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
SG11201811280QA (en) 2016-06-23 2019-01-30 Ablynx Nv Improved pharmacokinetic assays for immunoglobulin single variable domains
CN110049997B (en) 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 Improved serum albumin binding immunoglobulin single variable domains
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
BR112019014600A2 (en) 2017-01-17 2020-02-18 Ablynx N.V. IMPROVED SERUM ALBUMIN BINDERS
CA3056727A1 (en) 2017-03-31 2018-10-04 Ablynx N.V. Improved immunogenicity assays
CN112121147B (en) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 Application of polypeptide in medicine for treating or preventing myeloma, polypeptide, nucleic acid, medicine and recombinant expression vector
CN112592402B (en) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 anti-DKK 2 antibodies, compositions comprising the anti-DKK 2 antibodies, and uses thereof
CA3238160A1 (en) * 2021-11-18 2023-05-25 Aaron Sato Dickkopf-1 variant antibodies and methods of use
CN117384299B (en) * 2022-11-01 2024-04-30 邦恩泰(山东)生物医药科技集团股份有限公司 Chimeric antigen receptor targeting BCMA and/or FCRH5, CAR-T cells and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084344A2 (en) * 2006-01-13 2007-07-26 Novartis Ag Compositions and methods of use for antibodies of dickkopf-1 and/or -4
WO2008097510A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084344A2 (en) * 2006-01-13 2007-07-26 Novartis Ag Compositions and methods of use for antibodies of dickkopf-1 and/or -4
WO2008097510A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE GENST E ET AL: "Antibody repertoire development in camelids", DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, PERGAMON PRESS, US LNKD- DOI:10.1016/J.DCI.2005.06.010, vol. 30, no. 1-2, 1 January 2006 (2006-01-01), pages 187 - 198, XP025088320, ISSN: 0145-305X, [retrieved on 20060101] *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.79.6.1979, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424 *
SAERENS D ET AL: "Single-domain antibodies as building blocks for novel therapeutics", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL LNKD- DOI:10.1016/J.COPH.2008.07.006, vol. 8, no. 5, 1 October 2008 (2008-10-01), pages 600 - 608, XP025609339, ISSN: 1471-4892, [retrieved on 20080822] *

Also Published As

Publication number Publication date
WO2010130832A2 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2010130830A3 (en) Anti-sclerostin vhh and their use for treating bone diseases
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2009153496A3 (en) Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
WO2012058393A3 (en) Dkk1 antibodies and methods of use
WO2012080727A3 (en) Casein kinase 1delta (ck1delta) inhibitors
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2007081710A3 (en) Treatment modalities for autoimmune diseases
IL195142A (en) Substituted arylimidazolone and triazolone, process for their preparation and pharmaceutical compositions comprising the same for the treatment or prophylaxis of diseases
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MY167804A (en) Treatment of degenerative joint disease
WO2008093058A3 (en) Peptides and their use
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
MY160560A (en) Compositions and methods for treatment of kidney disorders
WO2008107092A3 (en) Use of derivatives of 4-hydroxyphenoxy acetic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10721768

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10721768

Country of ref document: EP

Kind code of ref document: A2